CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
AUTOR(ES)
Wasan, H S
FONTE
Nature Publishing Group
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2768104Documentos Relacionados
- Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma.
- Elevated serum CA 19-9 levels in patients with pulmonary nontuberculous mycobacterial disease
- CA 19-9 levels in patients with acute pancreatitis due to gallstone and metabolic/toxic reasons
- Comparison of Urinary and Serum CA 19-9 as Markers of Early Stage Urothelial Carcinoma
- Níveis séricos pré-operatórios de CA 72-4, CEA, CA 19-9 e Alfa-fetoproteína em pacientes com câncer gástrico